Theralase Technologies Inc. announced significant preclinical results showing that its lead formulation, Ruvidar(TM), is more effective than acyclovir in targeting herpes simplex virus type 1 (HSV-1). These results position Ruvidar(TM) as a powerful alternative to traditional antiviral treatments.
Studies conducted at the University of Manitoba demonstrate that Ruvidar(TM) not only outperforms Acyclovir in inhibiting virus replication, but is also effective when given after infection. It is superior to Acyclovir, which fails to prevent HSV-1 replication if added one day after infection. Notably, Ruvidar(TM) reduced HSV-1 replication by 10 million-fold under these conditions.
Theralase CEO Roger DuMoulin-White says the company is now seeking partnerships or licensing opportunities to advance Ruvidar(TM) for topical and oral treatments targeting herpes simplex.
These results highlight the potential of Ruvidar(TM) in the antiviral drug market, which is expected to reach USD 71.1 billion by 2032, and offer new perspectives for prophylactic and therapeutic applications.
R. H.
